SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-130240
Filing Date
2021-04-26
Accepted
2021-04-26 06:15:28
Documents
8

Document Format Files

Seq Description Document Type Size
1 DEFA14A d174244ddefa14a.htm DEFA14A 35917
2 GRAPHIC g174244g08v06.jpg GRAPHIC 888
3 GRAPHIC g174244g30x46.jpg GRAPHIC 1192
4 GRAPHIC g174244g42i27.jpg GRAPHIC 2541
5 GRAPHIC g174244g61z87.jpg GRAPHIC 1376
6 GRAPHIC g174244g75a36.jpg GRAPHIC 1282
7 GRAPHIC g174244g89p37.jpg GRAPHIC 958
8 GRAPHIC g174244g90f94.jpg GRAPHIC 1273
  Complete submission text file 0001193125-21-130240.txt   51055
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39269 | Film No.: 21851463
SIC: 2834 Pharmaceutical Preparations